What We're Reading: Page 96
Industry reads hand-picked by our editors
Feb 28, 2023
Feb 27, 2023
Feb 24, 2023
-
The New York Times
After Long Delay, Moderna Pays N.I.H. for Covid Vaccine Technique
-
Reuters
First Zantac cancer risk trial in California postponed by months
-
Evaluate Vantage
US deal watchdog’s bark could be worse than its bite
-
Nature
Data hint at Russia’s shifting science collaborations after year of war
Feb 23, 2023
-
Reuters
Senator Warren urges U.S. patent office to scrutinize Merck’s Keytruda
-
Fierce Biotech
AbbVie pays $70M to expand Capsida collab into eye disease
-
The Wall Street Journal
Wall Street Backs New Class of Psychedelic Drugs
Feb 22, 2023
-
The Boston Globe
‘We can’t take our foot off the gas now’: MassBio’s new CEO takes the reins.
-
Science
Case studies expose deadly risk of mpox to people with untreated HIV
-
Financial Times
AbbVie accused of overcharging Dutch for flagship drug Humira
-
FirstWord Pharma
Alnylam’s effort to expand Onpattro use to go before FDA panel
Feb 21, 2023
-
Associated Press
FDA’s own reputation could be restraining its misinfo fight
-
Stat News
Travere Therapeutics drug approved for rare kidney disease
-
The New York Times
A Fraught New Frontier in Telehealth: Ketamine
-
The Washington Post
Paul Berg, Nobel biochemist who first spliced DNA, dies at 96
Feb 17, 2023
-
BioCentury
Texas abortion ruling could undermine FDA
-
Kaiser Health News
Mark Cuban Has Been Taking On the Drug Industry. But Which One?
-
Fierce Biotech
GSK stands by dumping cell therapies as oligo strategy heats up
-
Bloomberg
Vaccine-Stockpiling Agency Gets a Revamp After Covid Lessons
Previous
